
Petros Perros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1110618/publications.pdf Version: 2024-02-01



DETROS DEDROS

#	Article	IF	CITATIONS
1	The enigma of persistent symptoms in hypothyroid patients treated with levothyroxine: A narrative review. Clinical Endocrinology, 2023, 98, 461-468.	2.4	33
2	Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey. Endocrinologia, Diabetes Y NutriciA"n, 2022, 69, 520-529.	0.3	11
3	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Hellenic Endocrine Society Hormones, 2022, 21, 103-111.	1.9	13
4	Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France. Annales D'Endocrinologie, 2022, 83, 27-34.	1.4	11
5	Primary hypothyroidism and quality of life. Nature Reviews Endocrinology, 2022, 18, 230-242.	9.6	55
6	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* survey of Belgian specialists *THESIS: treatment of hypothyroidism in Europe by specialists: an international survey. Thyroid Research, 2022, 15, 3.	1.5	12
7	Health care access of thyroid disease patients in Serbia during the COVID-19 pandemic. Journal of Endocrinological Investigation, 2022, , 1.	3.3	0
8	Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 2022, 97, 664-675.	2.4	3
9	Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Czech Society of Endocrinology. BMC Endocrine Disorders, 2022, 22, 117.	2.2	10
10	A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An) Tj ETQq0 0 0 rgB ⁻ 577-586.	T /Overloc 1.2	k 10 Tf 50 38 12
11	Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?. International Journal of Endocrinology and Metabolism, 2022, 20, .	1.0	1
12	Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace―and "titratior regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. Journal of Endocrinological Investigation, 2021, 44, 371-378.	n― 3.3	8
13	New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?. Thyroid, 2021, 31, 193-201.	4.5	43
14	Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. Clinical Endocrinology, 2021, 94, 513-520.	2.4	53
15	Recent evidence sets therapeutic targets for levothyroxine-treated patients with primary hypothyroidism based on risk of death. European Journal of Endocrinology, 2021, 184, C1-C3.	3.7	10
16	Use of thyroid hormones in hypothyroid and euthyroid patients: A 2020 THESIS questionnaire survey of members of the Danish Endocrine Society. Journal of Endocrinological Investigation, 2021, 44, 2435-2444.	3.3	23
17	Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians. *THESIS: Treatment of hypothyroidism in Europe by specialists: an international survey. Endokrynologia Polska, 2021, 72, 357-365.	1.0	18
18	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society. Frontiers in Endocrinology, 2021, 12, 795111.	3.5	16

#	Article	IF	CITATIONS
19	A survey on the psychological impact and access to health care of thyroid patients during the first SARS OVâ€2 lockdown. Clinical Endocrinology, 2021, , .	2.4	9
20	Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey. European Thyroid Journal, 2020, 9, 25-31.	2.4	34
21	A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye, 2020, 34, 1662-1671.	2.1	4
22	New Therapeutic Horizons for Graves' Hyperthyroidism. Endocrine Reviews, 2020, 41, 873-884.	20.1	56
23	Asymmetric Graves' Orbitopathy. Frontiers in Endocrinology, 2020, 11, 611845.	3.5	9
24	Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 2020, 43, 1717-1722.	3.3	15
25	Differentiated thyroid cancer mortality by disease stage in northern England. Clinical Endocrinology, 2020, 93, 61-66.	2.4	2
26	Weight gain following treatment of hyperthyroidism—A forgotten tale. Clinical Obesity, 2019, 9, e12328.	2.0	34
27	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	4.5	72
28	Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1. European Endocrinology, 2019, 15, 95.	1.5	19
29	Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	3.7	59
30	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	11.4	128
31	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-Related Cancer, 2018, 25, 309-322.	3.1	103
32	Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. Annals of Oncology, 2018, 29, viii470-viii471.	1.2	1
33	The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations. , 2018, , 7-15.		1
34	A decade of thyroidology. Hormones, 2018, 17, 491-495.	1.9	3
35	A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. Eye, 2018, 32, 1555-1562.	2.1	26
36	Phaeochromocytomas/paragangliomas and adverse clinical outcomes in patients with Neurofibromatosis type 1. Endocrine Connections, 2018, 7, R254-R259.	1.9	7

#	Article	IF	CITATIONS
37	Assessment of normal reference values for thyroid uptake of technetium-99m pertechnetate in a single centre UK population. Nuclear Medicine Communications, 2018, 39, 834-838.	1.1	15
38	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	3.3	57
39	Tremelimumab-Induced Graves Hyperthyroidism. European Thyroid Journal, 2017, 6, 167-170.	2.4	42
40	Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit, 2017, 36, 159-169.	0.8	11
41	Improving the prehospital safety of steroidâ€dependent patients in northern England: A hospitalâ€initiated ambulance service registration pathway. Clinical Endocrinology, 2017, 87, 881-882.	2.4	2
42	Raising awareness of Graves' orbitopathy with early warning cards. Clinical Endocrinology, 2017, 87, 853-859.	2.4	3
43	Novel Immunomodulatory Treatment Modalities. , 2017, , 177-192.		Ο
44	The Amsterdam Declaration on Graves' Orbitopathy. , 2017, , 338-344.		1
45	Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases, 2017, 12, 72.	2.7	113
46	Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology, 2016, 84, 799-808.	2.4	149
47	Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology and Otology, 2016, 130, S150-S160.	0.8	184
48	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
49	Serum thyroglobulin in the monitoring of differentiated thyroid cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S119-S123.	1.2	14
50	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease, 2016, 48, 552-558.	0.9	44
51	Hypothyroxinemia, Hyperthyrotropinemia, and Radioiodine: Partners in Crime Against Graves Orbitopathy?. AACE Clinical Case Reports, 2015, 1, e145-e146.	1.1	Ο
52	Metastatic Midgut Carcinoid in the Myocardium. Clinical Nuclear Medicine, 2015, 40, e446-e447.	1.3	1
53	Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E458-E462.	3.6	11
54	The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines. Pituitary, 2015, 18, 568-574.	2.9	40

#	Article	IF	CITATIONS
55	Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical Medicine, 2015, 15, 173-178.	1.9	33
56	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	3.9	92
57	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. Thyroid, 2015, 25, 1181-1184.	4.5	8
58	Thyroglobulin in differentiated thyroid cancer. Clinica Chimica Acta, 2015, 444, 310-317.	1.1	24
59	Medical Management of Mild and Moderate to Severe Thyroid Eye Disease. , 2015, , 83-88.		0
60	Saving lives of inâ€patients with adrenal insufficiency: implementation of an alert scheme within the Newcastleâ€uponâ€Tyne Hospitals eâ€Prescribing platform. Clinical Endocrinology, 2014, 81, 937-938.	2.4	7
61	Pilot of <i><scp>BRAF</scp></i> mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology, 2014, 25, 146-154.	0.7	37
62	Novel Thermal Imaging Analysis Technique for Detecting Inflammation in Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4600-4606.	3.6	20
63	Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis. European Thyroid Journal, 2014, 3, 245-251.	2.4	20
64	Residual Adrenal Function in Autoimmune Addison's Disease: Improvement After Tetracosactide (ACTH _{1–24}) Treatment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 111-118.	3.6	31
65	Guidelines for the management of thyroid cancer. Clinical Endocrinology, 2014, 81, 1-122.	2.4	961
66	Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study Journal of Clinical Oncology, 2014, 32, 4111-4111.	1.6	0
67	The effect of B cell depletion therapy on antiâ€< scp>TSH receptor antibodies and clinical outcome in glucocorticoidâ€refractory Graves' orbitopathy. Clinical Endocrinology, 2013, 79, 437-442.	2.4	64
68	ls Recombinant Human TSH a Trigger for GravesÂ' Orbitopathy?. European Thyroid Journal, 2012, 1, 105-109.	2.4	9
69	European Thyroid Association Guidelines on L-T4 + L-T3 Combination for Hypothyroidism: A Weary Step in the Right Direction. European Thyroid Journal, 2012, 1, 51-54.	2.4	16
70	An Unusual Presenting Symptom of GravesÂ' Disease: Myalgia. European Thyroid Journal, 2012, 1, 274-6.	2.4	2
71	Orbital decompression for Graves' orbitopathy in England. Eye, 2012, 26, 434-437.	2.1	6
72	Management plan and delivery of care in Graves' ophthalmopathy patients. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 303-311.	4.7	7

#	Article	IF	CITATIONS
73	Carcinoid Tumour in an lleocystoplasty: A Reminder to Consider Native Bowel Disease in the Reconstructed Urinary Tract. British Journal of Medical and Surgical Urology, 2011, 4, 39-41.	0.2	2
74	Rising Serum 25-Hydroxyvitamin D Levels After Weight Loss in Obese Women Correlate With Improvement in Insulin Resistance. Obstetrical and Gynecological Survey, 2011, 66, 23-24.	0.4	0
75	Clinical Spectrum of Graves Orbitopathy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 83-89.	0.5	0
76	2009 American Thyroid Association Guidelines on Thyroid Nodules. Clinical Oncology, 2010, 22, 469-471.	1.4	6
77	Metachronous testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases. European Journal of Cancer Care, 2010, 19, 701-702.	1.5	1
78	General Management Plan. , 2010, , 88-95.		0
79	Rising Serum 25-Hydroxy-Vitamin D Levels after Weight Loss in Obese Women Correlate with Improvement in Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4251-4257.	3.6	140
80	The Amsterdam Declaration on Graves' Orbitopathy. Thyroid, 2010, 20, 245-246.	4.5	30
81	The Amsterdam Declaration on Graves' Orbitopathy. , 2010, , 265-270.		0
82	The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. European Journal of Endocrinology, 2009, 161, 483-487.	3.7	51
83	The Management of Hypogonadism in Aging Male Patients. Postgraduate Medicine, 2009, 121, 113-121.	2.0	5
84	SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Familial Cancer, 2009, 8, 257-260.	1.9	61
85	Graves orbitopathy: a perspective. Nature Reviews Endocrinology, 2009, 5, 312-318.	9.6	13
86	Thyroid-Associated Orbitopathy: Who and How to Treat. Endocrinology and Metabolism Clinics of North America, 2009, 38, 373-388.	3.2	25
87	Thyroid eye disease. BMJ: British Medical Journal, 2009, 338, b560-b560.	2.3	71
88	Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe. Clinical Endocrinology, 2008, 69, 951-956.	2.4	16
89	Use of Somatostatin Analogues in Obesity. Drugs, 2008, 68, 1963-1973.	10.9	28
90	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	3.7	611

#	Article	IF	CITATIONS
91	DeclaraciÃ ³ n de consenso del Grupo europeo sobre la orbitopatÃa de Graves (EUGOGO) sobre el tratamiento de la orbitopatÃa de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0
92	Erectile Dysfunction in Patients with Hyper- and Hypothyroidism: How Common and Should We Treat?. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1815-1819.	3.6	103
93	Thyroid autoimmunity, infertility and miscarriage. Expert Review of Endocrinology and Metabolism, 2008, 3, 127-136.	2.4	15
94	Mortality from thyroid cancer in patients with hyperthyroidism: the Theagenion Cancer Hospital experience. European Journal of Endocrinology, 2008, 159, 799-803.	3.7	41
95	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
96	Detection of Hurthle Cell Carcinoma Using Sestamibi. Thyroid, 2008, 18, 575-576.	4.5	4
97	Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. British Journal of Ophthalmology, 2007, 91, 455-458.	3.9	253
98	A Patient with Asymmetric Parotid Uptake on a Diagnostic Iodine-131 Scan during Thyroid Cancer Follow-Up. Thyroid, 2007, 17, 801-802.	4.5	2
99	A 52-Year-Old Female with a Hoarse Voice and Tingling in the Hand. PLoS Medicine, 2007, 4, e29.	8.4	0
100	Milk alkali syndrome without the milk. BMJ: British Medical Journal, 2007, 335, 397-398.	2.3	12
101	Psychological implications of Graves' orbitopathy. European Journal of Endocrinology, 2007, 157, 127-131.	3.7	95
102	Genomic Polymorphism at the Interferon-Induced Helicase (IFIH1) Locus Contributes to Graves' Disease Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3338-3341.	3.6	104
103	Introduction to the updated guidelines on the management of thyroid cancer. Clinical Medicine, 2007, 7, 321-322.	1.9	18
104	General Management Plan. , 2007, , 88-95.		9
105	Plasma endothelin response to acute hypoglycaemia in adults with TypeÂ1 diabetes. Diabetic Medicine, 2007, 24, 1039-1042.	2.3	22
106	Fatal inflammatory hypophysitis. Pituitary, 2007, 10, 107-111.	2.9	27
107	Prevention of thyroid associated-ophthalmopathy in children and adults: current views and management of preventable risk factors. Pediatric Endocrinology Reviews, 2007, 4, 218-24.	1.2	10
108	A questionnaire survey on the management of Graves' orbitopathy in Europe. European Journal of Endocrinology, 2006, 155, 207-211.	3.7	68

#	Article	IF	CITATIONS
109	Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clinical Endocrinology, 2006, 65, 186-190.	2.4	82
110	Cushing's syndrome without excess cortisol. BMJ: British Medical Journal, 2006, 332, 469-470.	2.3	18
111	What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. European Journal of Endocrinology, 2006, 154, 783-786.	3.7	44
112	Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology, 2006, 155, 387-389.	3.7	247
113	Thyrotoxicosis and Pregnancy. PLoS Medicine, 2005, 2, e370.	8.4	2
114	A 69-Year-Old Female with Tiredness and a Persistent Tan. PLoS Medicine, 2005, 2, e229.	8.4	0
115	rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer, 2005, 12, 49-64.	3.1	154
116	A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Graves' Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5321-5323.	3.6	139
117	Early Response to Intravenous Glucocorticoids for Severe Thyroid-Associated Ophthalmopathy Predicts Treatment Outcome. Journal of Ocular Pharmacology and Therapeutics, 2005, 21, 328-336.	1.4	46
118	Influence of an Early-Onset Age of Type 1 Diabetes on Cerebral Structure and Cognitive Function. Diabetes Care, 2005, 28, 1431-1437.	8.6	208
119	Analysis of Peripheral Blood T-Cell Subsets in Active Thyroid-Associated Ophthalmopathy: Absence of Effect of Octreotide-LAR on T-Cell Subsets in Patients with Thyroid-Associated Ophthalmopathy. Thyroid, 2005, 15, 1073-1078.	4.5	5
120	Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5910-5915.	3.6	81
121	Role of the CD40 Locus in Graves' Disease. Thyroid, 2004, 14, 506-509.	4.5	55
122	Serum Thyrotropin is a Better Predictor of Future Thyroid Dysfunction Than Thyroid Autoantibody Status in Biochemically Euthyroid Patients with Diabetes: Implications for Screening. Thyroid, 2004, 14, 853-857.	4.5	31
123	The Codon 620 Tryptophan Allele of the Lymphoid Tyrosine Phosphatase (LYP) Gene Is a Major Determinant of Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5862-5865.	3.6	416
124	Pituitary Apoplexy: A Review of Clinical Presentation, Management and Outcome in 45 Cases. Pituitary, 2004, 7, 157-163.	2.9	268
125	A New Assay for Thyrotropin Receptor Autoantibodies. Thyroid, 2004, 14, 830-835.	4.5	95
126	A New Assay for Thyrotropin Receptor Autoantibodies. Thyroid, 2004, 14, 830-835.	4.5	78

8

#	Article	IF	CITATIONS
127	Multiple endocrine neoplasia type 2A. Cancer Genetics and Cytogenetics, 2003, 141, 157-159.	1.0	13
128	Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma. Cancer, 2003, 98, 41-47.	4.1	31
129	CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clinical Endocrinology, 2003, 58, 732-735.	2.4	60
130	Role of serum thyroglobulin measurement in patients with thyroid nodules. Clinical Endocrinology, 2003, 59, 657-657.	2.4	1
131	The Impact of Clinical Guidelines on Surgical Management in Patients with Thyroid Cancer. Clinical Oncology, 2003, 15, 485-489.	1.4	11
132	Thyroid disease and male reproductive function. Journal of Endocrinological Investigation, 2003, 26, 372-380.	3.3	50
133	Radioiodine Uptake in Normal Female Breasts and Liver of a Patient with Differentiated Thyroid Cancer Imaged by Whole Body Scanning. Thyroid, 2003, 13, 511-511.	4.5	5
134	Cognitive Ability and Brain Structure in Type 1 Diabetes. Diabetes, 2003, 52, 149-156.	0.6	270
135	Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. European Journal of Endocrinology, 2003, 148, 491-495.	3.7	187
136	Apolipoprotein-E Influences Aspects of Intellectual Ability in Type 1 Diabetes. Diabetes, 2003, 52, 145-148.	0.6	23
137	Glucocorticoids in the medical management of Graves' ophthalmopathy. Minerva Endocrinologica, 2003, 28, 223-31.	1.8	4
138	Medical Treatment for Thyroid-Associated Ophthalmopathy. Thyroid, 2002, 12, 241-244.	4.5	12
139	Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose?. Clinical Endocrinology, 2002, 56, 689-691.	2.4	10
140	Management of recurrent pituitary cysts with pituitary-nasal drain. Pituitary, 2002, 5, 225-233.	2.9	6
141	Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester. Clinical Endocrinology, 2001, 54, 559-561.	2.4	17
142	Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clinical Endocrinology, 2001, 55, 283-303.	2.4	160
143	Serum S-100β protein as a biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. Diabetic Medicine, 2001, 18, 1008-1008.	2.3	2
144	Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement. BMJ: British Medical Journal, 2001, 323, 332-333.	2.3	36

#	Article	IF	CITATIONS
145	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 626-630.	3.6	54
146	Evidence for a Graves' Disease Susceptibility Locus at Chromosome Xp11 in a United Kingdom Population. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 626-630.	3.6	54
147	Clinical Presentation and Natural History of Graves' Ophthalmopathy. Growth Hormone, 2001, , 119-136.	0.2	2
148	Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes/Metabolism Research and Reviews, 2000, 16, 211-216.	4.0	17
149	Evaluation of an on-call diabetes service in a large teaching hospital. Diabetic Medicine, 2000, 17, 386-389.	2.3	4
150	Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis. Diabetic Medicine, 2000, 17, 807-809.	2.3	25
151	Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabetic Medicine, 2000, 17, 749-751.	2.3	49
152	Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace?. Clinical Endocrinology, 2000, 53, 1-2.	2.4	12
153	Lack of Antigenicity of Recombinant Human Thyrotropin After Multiple Injections in Patients with Differentiated Thyroid Cancer. Thyroid, 2000, 10, 623-623.	4.5	8
154	Evidence for a New Graves Disease Susceptibility Locus at Chromosome 18q21. American Journal of Human Genetics, 2000, 66, 1710-1714.	6.2	64
155	Association Analysis of the Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Autoimmune Regulator-1 (AIRE-1) Genes in Sporadic Autoimmune Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 688-691.	3.6	73
156	Optimizing the Management of Differentiated Thyroid Cancer. Clinical Oncology, 2000, 12, 363-364.	1.4	5
157	Do diabetes guidelines influence the content of referral letters by general practitioners to a diabetes specialist clinic?. Health Bulletin, 2000, 58, 322-7.	0.1	3
158	The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics, 1999, 8, 1195-1199.	2.9	203
159	Severe Thyroid Eye Disease Associated with Primary Hypothyroidism and Thyroid-Associated Dermopathy. Thyroid, 1999, 9, 1115-1118.	4.5	21
160	Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes/Metabolism Research and Reviews, 1999, 15, 5-12.	4.0	29
161	Further Evidence for a Susceptibility Locus on Chromosome 20q13.11 in Families with Dominant Transmission of Graves Disease. American Journal of Human Genetics, 1999, 65, 1462-1465.	6.2	53
162	Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet, The, 1999, 354, 743-744.	13.7	119

#	Article	IF	CITATIONS
163	Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. Journal of Endocrinological Investigation, 1999, 22, 30-4.	3.3	12
164	Factors influencing preference of insulin regimen in people with type 1 (insulin–dependent) diabetes. Diabetes Research and Clinical Practice, 1998, 39, 23-29.	2.8	15
165	Natural History of Thyroid Eye Disease. Thyroid, 1998, 8, 423-425.	4.5	81
166	Clinical Presentation of Thyroid Associated Orbitopathy. Thyroid, 1998, 8, 427-428.	4.5	51
167	The Long-Term Sequelae of Severe Hypoglycemia on the Brain in Insulin-Dependent Diabetes Mellitus. Hormone and Metabolic Research, 1997, 29, 197-202.	1.5	25
168	Brain Abnormalities Demonstrated by Magnetic Resonance Imaging in Adult IDDM Patients With and Without a History of Recurrent Severe Hypoglycemia. Diabetes Care, 1997, 20, 1013-1018.	8.6	130
169	Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively?. , 1997, 14, 482-486.		53
170	An Audit of Waiting Times in the Diabetic Outpatient Clinic: Role of Patients' Punctuality and Level of Medical Staffing. Diabetic Medicine, 1996, 13, 669-673.	2.3	15
171	Non-islet cell tumour-associated hypoglycaemia: 111 In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clinical Endocrinology, 1996, 44, 727-731.	2.4	54
172	Altered Taste Sensation in Newly-Diagnosed NIDDM. Diabetes Care, 1996, 19, 768-770.	8.6	76
173	Natural history of thyroid associated ophthalmopathy. Clinical Endocrinology, 1995, 42, 45-50.	2.4	196
174	Frequency of Thyroid Dysfunction in Diabetic Patients: Value of Annual Screening. Diabetic Medicine, 1995, 12, 622-627.	2.3	312
175	Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 115-135.	1.0	40
176	Chronic Pontine Dysfunction Following Insulin-Induced Hypoglycemia in an IDDM Patient. Diabetes Care, 1994, 17, 725-727.	8.6	20
177	Anti-mitochondrial antibodies in patients with Graves' disease may not signify primary biliary cirrhosis Postgraduate Medical Journal, 1994, 70, 17-18.	1.8	1
178	Demonstration of thyrotropin binding sites in orbital connective tissue: Possible role in the pathogenesis of thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 1994, 17, 163-170.	3.3	40
179	Age and gender influence the severity of thyroidâ€associated ophthalmopathy: a study of 101 patients attending a combined thyroidâ€eye clinic. Clinical Endocrinology, 1993, 38, 367-372.	2.4	218
180	Pathogenesis of thyroid-associated ophthalmopathy. Trends in Endocrinology and Metabolism, 1993, 4, 270-275.	7.1	16

#	Article	IF	CITATIONS
181	Autoantibodies to Igf-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity, 1993, 16, 251-257.	2.6	119
182	Antibodies to orbital tissues in thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1992, 126, 137-142.	3.7	10
183	Pathogenetic mechanisms in thyroidâ€associated ophthalmopathy. Journal of Internal Medicine, 1992, 231, 205-211.	6.0	16
184	Biological activity of autoantibodies from patients with thyroid-associated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. The Quarterly Journal of Medicine, 1992, 84, 691-706.	1.0	8
185	Measurement of cell proliferation by enzymeâ€linked immunosorbent assay (ELISA) using a monoclonal antibody to bromodeoxyuridine. Cell Proliferation, 1991, 24, 517-523.	5.3	40
186	Azathioprine in the treatment of thyroid-associated ophthalmopathy. European Journal of Endocrinology, 1990, 122, 8-12.	3.7	69
187	The pathogenesis of thyroid-associated ophthalmopathy. Journal of Endocrinology, 1989, 122, 619-624.	2.6	24
188	Psoas abscess due to retroperitoneal tuberculous lymphadenopathy. Tubercle, 1988, 69, 299-301.	0.6	8
189	DIFFERENTIATION OF AUTOIMMUNE OPHTHALMOPATHY FROM GRAVES' HYPERTHYROIDISM BY ANALYSIS C GENETIC MARKERS. Clinical Endocrinology, 1988, 28, 601-610.)F _{2.4}	24
190	Long-Term Effects of Hypoglycaemia on Cognitive Function and the Brain in Diabetes. , 0, , 285-307.		4
191	Adrenal Cortical Carcinoma. , 0, , 137-141.		0